Image Credit: depositphotos.com
Scientists at the Institute for Bioengineering of Catalonia have made a significant breakthrough in vision restoration, developing light-activated compounds that can restore light perception and visually guided behavior in blind animal models. This innovative approach does not rely on gene therapy, implants, or specialized equipment, with two of the most promising compounds being administered as simple eye drops.
The research, published in the Journal of the American Chemical Society, addresses critical conditions such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), which collectively impact approximately 200 million people worldwide. These conditions also carry a substantial economic burden, costing an estimated $400 billion annually in healthcare expenses and lost productivity.
Many existing treatments have limitations. When photoreceptor cells in the retina deteriorate, the visual system struggles to convert light into neural signals effectively, although some retinal circuitry remains functional. Current gene therapies are effective only for patients with specific genetic mutations, representing a small subset of those affected. While retinal prostheses can assist some individuals, they are invasive, expensive, and require extensive training to use effectively. Other methods, such as optogenetics and light-responsive drugs, have shown promise in clinical trials, but reliably restoring vision under normal light conditions remains a challenge.
The research team utilized an innovative approach known as photopharmacology, which incorporates a light-sensitive molecular switch into the drug’s structure. This allows the compound’s activity to change in response to light. The compounds, named prosthe6, are designed to substitute for the lost photoreceptors, aiming to reactivate the retinal circuit at the same level where the photoreceptor cells have degenerated.
The experiments demonstrated that prosthe6 compounds effectively target ON-bipolar neurons, which are responsible for transmitting signals from photoreceptors deeper into the retinal network. In blinded zebrafish larvae, these compounds successfully restored saccadic eye movements. Additionally, in mouse models of AMD and RP, the compounds helped restore instinctive preferences for darker environments that are typically observed in sighted mice but lost in blind counterparts.
Notably, blind mice treated with prosthe6 compounds began to instinctively avoid brightly lit areas without any prior training, achieving this at light levels comparable to indoor or overcast conditions. Among the compounds tested, prosthe6-12 and prosthe6-15 demonstrated particularly promising results.
While these compounds show remarkable effectiveness in restoring sight, they do not address the underlying causes of photoreceptor degeneration. The ongoing research aims to develop a treatment that could potentially benefit patients who do not qualify for gene therapy. Plans are in place to advance this research into clinical testing, aided by the formation of a spin-off company dedicated to bringing this therapy to human patients.
Check out the original article here: Source link
